key: cord-0689574-crauep1b
authors: Shah, Pinak B.; Welt, Frederick G.P.; Mahmud, Ehtisham; Phillips, Alistair; Anwaruddin, Saif
title: Reply: Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC/SCAI Consensus Statement
date: 2020-07-13
journal: JACC Cardiovasc Interv
DOI: 10.1016/j.jcin.2020.05.035
sha: c9bb6879b68503954de6f89e572ae7f25bbdea0c
doc_id: 689574
cord_uid: crauep1b

nan

We read with interest letters from Shreenivas et al. (1) from The Christ Hospital in Cincinnati and Li et al. (2) from Radboud University in the Netherlands First, they use V max $5.0 m/s or mean gradient $50 mm Hg on echocardiography as criteria for urgent TAVR, independent of symptom status.

Because this remains an issue for ongoing investigation even before the COVID-19 pandemic, the writing group was hesitant to offer strict hemodynamic criteria for urgent TAVR during COVID-19, deferring to local judgement on a case-by-case basis.

Second, they have moved to performing TAVR with general anesthesia rather than conscious sedation during the COVID-19 pandemic to minimize risk of staff exposure during unexpected intubation. The benefits of avoiding general anesthesia for TAVR include rapid recovery, avoidance of the intensive care unit, and rapid discharge. Furthermore, a recent TVT registry analysis suggests that conscious sedation is associated with reduced mortality in patients undergoing TAVR (3) . It is understood, however, that physician and staff safety must be considered, and balancing these goals is challenging. This decision is best made locally and will be easier with widespread COVID-19 testing. We do believe, however, the net benefit is toward avoidance of general anesthesia.

Li et al. (2) raise an important concern regarding the potential risk for outpatients referred for intervention. There is recognition of the risk of transmission from asymptomatic carriers of the novel coronavirus, insufficient local epidemiological data, variable availability of widespread testing, and a poor understanding of immunity. Furthermore, given the age and comorbid conditions of many patients with structural heart disease, the consequence of COVID-19 infection may be more severe than in the general population. We recognize that for each patient requiring intervention, a balance must be struck be- (4) estimated that 1,148 patients would be needed to adequately power a trial to assess graft patency, and almost 5,800 patients are needed to assess major adverse cardiac and cerebrovascular events.

Given that future randomized trials are unlikely, the available evidence suggests that: 1) FFR-guided CABG is associated with fewer grafts compared with angiography-guided CABG, which may facilitate off-pump and minimally invasive techniques; 2) FFRguided CABG is at least as good as angiographyguided CABG with regard to angiographic and clinical outcomes at follow-up ranging from 6 months to 6 years; 3) whether these findings justify a paradigm shift to deviate from the traditional approach of complete angiographic revascularization remains controversial; and 4) FFR may be considered a complementary tool that could guide the use of arterial conduits when FFR is #0.78, as described in an observational study involving 68 patients (6).

*Christopher Cao, MBBS, BSc, PhD

Triage considerations for patients referred for structural heart disease intervention during the coronavirus disease 2019 (COVID-19) pandemic: an ACC /SCAI position statement

Performing structural heart disease interventions during the COVID-19 pandemic -but what are the downsides?

Conscious sedation versus general anesthesia for transcatheter aortic valve replacement: variation in practice and outcomes

Please note: The authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Cardiovascular Interventions author instructions page.